Recent Advances in Covalent Drug Discovery

Area of Science:

• Drug Discovery and Development
• Medicinal Chemistry
• Biochemistry

Background:

• Covalent inhibitors are an expanding area in drug discovery, with successful examples in kinase inhibition (e.g., ibrutinib, dacomitinib) and viral protease inhibition (e.g., boceprevir, nirmatrelvir).
• Covalent bonding offers advantages such as enhanced target selectivity, overcoming drug resistance, and enabling lower administration concentrations.
• The electrophilic warhead is critical for dictating selectivity, reactivity, and binding mode (reversible/irreversible), and is amenable to rational design.

Purpose of the Study:

• To review the current landscape of covalent inhibitor development.
• To provide a historical perspective on covalent drug design.
• To highlight emerging applications, including proteolysis-targeting chimeras (PROTACs) and antiviral therapies for SARS-CoV-2.

Main Methods:

• Literature review of covalent inhibitor development.
• Analysis of approved covalent drugs and their mechanisms.
• Exploration of PROTAC technology and its role in targeting 'undruggable' proteins.
• Review of covalent inhibitors in the context of viral infections, specifically SARS-CoV-2.

Main Results:

• Covalent inhibitors have achieved significant clinical success, particularly in oncology and virology.
• Rational design of electrophilic warheads allows for fine-tuning of inhibitor properties.
• Covalent inhibition is a key strategy in the development of PROTACs for targeted protein degradation.
• Covalent inhibitors are crucial in the therapeutic strategies against SARS-CoV-2.

Conclusions:

• Covalent inhibitors represent a powerful and versatile modality in modern drug discovery.
• Their application is expanding beyond traditional targets into areas like protein degradation via PROTACs.
• Continued innovation in warhead design and application holds promise for treating a wide range of diseases, including viral infections.